Eli Lilly and Almirall report promising results from phase III atopic eczema study
A collaboration between Spanish firm Almirall and US-based Eli Lilly has so far resulted in positive results from three of five global phase III studies with the drug lebrikizumab. Marketing rights for Europe and the rest of the world have been split between the firms.
by ulrich quistgaard, translated by daniel pedersen
Pharmaceutical giant Eli Lilly and Spanish dermatology company Almirall have come together to develop a treatment for atopic dermatitis, also known as atopic eczema.